VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 8, 2014) - Response Biomedical Corp. (TSX:RBM)(OTCBB:RPBIF) ("Response" or "the Company"), in accordance with the requirements of the Toronto Stock Exchange, is pleased to announce the results of voting at its 2013 Annual General Meeting of Shareholders held earlier today.
A total of 4,942,396 common shares were voted in connection with the meeting, representing approximately 62% of the issued and outstanding common shares of the Company. Shareholders voted as follows:
- Appointment of Auditor
By resolution passed by show of hands, PricewaterhouseCoopers LLP, Chartered Accountants, was appointed auditor of the Company for the ensuing year.
- Election of Directors
By resolution passed by show of hands, the number of directors of the Company was set at 8. By resolution passed by ballot vote, the following eight nominees proposed by management were elected as directors of the Company to hold office until the next annual meeting of Shareholders or until their successors are elected or appointed:
| Nominee | Votes For |
% Votes For |
Votes Withheld |
% Votes Withheld | ||||
| Dr. Anthony Holler, M.D. | 4,629,965 | 99.87% | 5,954 | 0.13% | ||||
| Dr. Joseph D. Keegan, Ph.D. | 4,629,984 | 99.87% | 5,935 | 0.13% | ||||
| Jeffrey L. Purvin | 4,629,710 | 99.87% | 6,209 | 0.13% | ||||
| Clinton H. Severson | 4,629,959 | 99.87% | 5,960 | 0.13% | ||||
| Lewis J. Shuster | 4,629,027 | 99.85% | 6,892 | 0.15% | ||||
| Dr. Peter A. Thompson, M.D. | 4,628,772 | 99.85% | 7,147 | 0.15% | ||||
| Dr. David G. Wang, M.D. | 4,628,797 | 99.85% | 7,122 | 0.15% | ||||
| Dr. Jonathan J. Wang, Ph.D. | 4,628,797 | 99.85% | 7,122 | 0.15% |
About Response Biomedical Corp.
Response develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP® Platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to any other medical and non-medical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, influenza A and B and RSV. In the non-clinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus and for Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.
Response is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
Contact Information:
W.J. (Bill) Adams
Chief Financial Officer
604-456-6010
ir@responsebio.com
www.responsebio.com